U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H18O2
Molecular Weight 206.2808
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FEZAGEPRAS

SMILES

CCCCCC1=CC=CC(CC(O)=O)=C1

InChI

InChIKey=PEGQOIGYZLJMIB-UHFFFAOYSA-N
InChI=1S/C13H18O2/c1-2-3-4-6-11-7-5-8-12(9-11)10-13(14)15/h5,7-9H,2-4,6,10H2,1H3,(H,14,15)

HIDE SMILES / InChI
PBI 4050, a synthetic analog of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, that was developed for managing inflammatory and fibrosis-related diseases. In addition, PBI-4050 may exert antifibrotic activity in the liver through a novel mechanism of action involving modulation of intracellular ATP levels and the LKB1/AMPK/mTOR pathway in stellate cells. This drug participated in clinical trials for the treatment of acute lung injury, cystic fibrosis, diabetic nephropathies; idiopathic pulmonary fibrosis; metabolic syndrome; scleroderma; type 2 diabetes mellitus. Besides, this drug has granted a Rare Pediatric Disease Designation for the treatment of Alström syndrome (AS). PBI-4050 was also previously granted Orphan Drug Designation by the FDA and the EMA for the treatments of AS and idiopathic pulmonary fibrosis (IPF) as well as PIM (Promising Innovative Medicine) designation by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of IPF and AS. The FDA grants Rare Pediatric Disease Designations for serious or life-threatening diseases wherein the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups, often called neonates, infants, children, and adolescents. Now Prometic Life Sciences plans to file investigational new drug application for pivotal phase III trial for Alstrom's syndrome in the second half of 2019.

Approval Year

PubMed

PubMed

TitleDatePubMed
A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84.
2018 May
Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control.
2018 May 17
Treatment with PBI-4050 in patients with Alström syndrome: study protocol for a phase 2, single-Centre, single-arm, open-label trial.
2018 Nov 26
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis.
2019 Mar
PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure.
2020 Jan 1

Sample Use Guides

Alström Syndrome: four 200 mg capsules (800 mg total) administered orally, once daily
Route of Administration: Oral
Name Type Language
FEZAGEPRAS
INN  
Official Name English
2-(3-PENTYLPHENYL)ACETIC ACID
Systematic Name English
SETOGEPRAM
INN  
Common Name English
PBI-4050
Code English
3-PENTYLBENZENEACETIC ACID
Systematic Name English
fezagepras [INN]
Common Name English
BENZENEACETIC ACID, 3-PENTYL-
Systematic Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/16/1810
Created by admin on Sat Dec 16 17:29:45 GMT 2023 , Edited by admin on Sat Dec 16 17:29:45 GMT 2023
Code System Code Type Description
FDA UNII
879OVM0Y1S
Created by admin on Sat Dec 16 17:29:45 GMT 2023 , Edited by admin on Sat Dec 16 17:29:45 GMT 2023
PRIMARY
PUBCHEM
24749700
Created by admin on Sat Dec 16 17:29:45 GMT 2023 , Edited by admin on Sat Dec 16 17:29:45 GMT 2023
PRIMARY
SMS_ID
100000177187
Created by admin on Sat Dec 16 17:29:45 GMT 2023 , Edited by admin on Sat Dec 16 17:29:45 GMT 2023
PRIMARY
CAS
1002101-19-0
Created by admin on Sat Dec 16 17:29:45 GMT 2023 , Edited by admin on Sat Dec 16 17:29:45 GMT 2023
PRIMARY
DRUG BANK
DB15447
Created by admin on Sat Dec 16 17:29:45 GMT 2023 , Edited by admin on Sat Dec 16 17:29:45 GMT 2023
PRIMARY
NCI_THESAURUS
C171674
Created by admin on Sat Dec 16 17:29:45 GMT 2023 , Edited by admin on Sat Dec 16 17:29:45 GMT 2023
PRIMARY
INN
10332
Created by admin on Sat Dec 16 17:29:45 GMT 2023 , Edited by admin on Sat Dec 16 17:29:45 GMT 2023
PRIMARY